Carbohydrates are fundamental molecules involved in nearly all aspects of lives, such as
being involved in formating the genetic and energy materials, supporting the structure of …

Fluoroorganic chemistry has become essential in the evolution of many different but
interconnected research fields. These include the development of new materials with a …

Background Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce hospitalizations
and death from heart failure (HF), but their effect on arrhythmia expression has been poorly …

Introduction Obesity is frequently a comorbidity of type 2 diabetes. Even modest weight loss
can significantly improve glucose homeostasis and lessen cardiometabolic risk factors in …

2 型糖尿病的特征是在不同的胰岛素靶组织如肝脏, 脂肪组织与骨骼肌中发生的胰岛素抵抗以及
来自胰腺β 细胞的胰岛素分泌量不足. 钠‐葡萄糖共转运体2 (SGLT2) 抑制剂是一种最新研制的 …

Guidelines RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2
Diabetes Mellitus 2020Table. No title available.

Background In patients with type 2 diabetes, sodium-glucose cotransporter-2 (SGLT2)
inhibitors are known to reduce glucose concentrations, blood pressure, and weight, but to …

Recent insights into the pathophysiologic underlying mechanisms of obesity have led to the
discovery of several promising drug targets and novel therapeutic strategies to address the …

Background The sodium‐glucose cotransporter 2 (SGLT 2) inhibitors are a class of oral
hypoglycemic agents. We undertake a systematic review and meta‐analysis of prospective …

Context: Canagliflozin is a sodium glucose cotransporter 2 inhibitor developed to treat type 2
diabetes mellitus (T2DM). Objective: The purpose of this study was to describe the effects of …